NCT05119296 2025-12-22Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerStanford UniversityPhase 2 Active not recruiting12 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT07010393 2025-06-08Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyFujian Medical UniversityPhase 4 Not yet recruiting335 enrolled
NCT04234113 2025-01-08Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid TumorsSotio Biotech Inc.Phase 1 Terminated115 enrolled
NCT05620134 2024-10-15Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerSalubris Biotherapeutics IncPhase 1/2 Active not recruiting263 enrolled
NCT05708950 2023-07-13A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)Kineta Inc.Phase 1/2 Unknown314 enrolled